Ionizable Lipid Products

Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR)

Shield-1 is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize the entire fusion protein[1][2].

5-Chloro-2'-deoxyuridine, a thymine analog, is to study the potential of hypochlorous acid damage to DNA and DNA precursors.

5M-8OH-Q is a specific small molecule inhibitor of UDP-glucose glycoprotein glucosyltransferase (UGGT), binds a CtUGGTGT24 “WY” conserved surface motif conserved across UGGTs (Kd=47 uM) but not present in other GT24 family glycosyltransferases.

CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling; exhibits inhibition of TNF release from RAW264.7 cells with EC50 of 12.6 nM, inhibits NF-κB reporter activity with IC50 of 22.5 nM; antagonizes NOD2 signaling by interfering with the XIAP-RIPK2 interaction, selectively inhibits NOD responses in cells (HEKBlue NOD2 IC50=26.3 nM) and displays potent activity in vivo, does not attenuates the TNF release following an unrelated pro-inflammatory stimulation mediated through TLR4 activation by LPS at 1 uM.

Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Solriamfetol binds to dopamine and norepinephrine transporters, so it can inhibit reuptake of dopamine and norepinephrine. Solriamfetol treatment significantly improves the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy.

TED-347 (TED347) is an irreversible inhibitor of TEAD4-Yap1 protein-protein interaction (EC50=5.9 uM in FP asssays) via covalent modification of conserved cysteine (Cys367, Ki=1.3 uM), inhibits its binding to Yap1, blocked its transcriptional activity; inhibits TEAD transcriptional activity and protein interactions in cells at 5 uM resulted in over 70% reduction in reporter activity; inhibits GBM43 cancer cell viability by 30% at 10 uM, also inhibits TEAD4 transcriptional activity in GBM43 cells.

17-AAG is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90.

Geldanamycin binds in the ATP-binding site in the N-terminus domain of Hsp90s (residues 1-220). Geldanamycin inhibits the ATPase activity of Hsp90 in a dose-dependent manner. Geldanamycin causes a dose-dependent G2 arrest and reversible inhibiton o f entry into the S phase in A2780 human ovarian cell line. This inhibition is accompanied by p53 increase and finally demonstrated to be p53 dependent. Geldanamycin causes polyubiquitination and proteasomal degradation of the p185 receptor protein-tyrosin kinase and shows a IC50 with 70 nM. [3, 4] Geldanamycin is a typical anti-tumor reagent, shows a mean GI50 with 0.18 μM against the panel of 60 human tumor cell lines. [5] Geldanamycin (50 mg//kg) shows 30% inhibition on pl85-associated phosphotyrosine levels in FRE/erbB-2 mice. [6]. For the detailed information of Geldanamycin (NSC122750), the solubility of Geldanamycin (NSC122750) in water, the solubility of Geldanamycin (NSC122750) in DMSO, the solubility of Geldanamycin (NSC122750) in PBS buffer, the animal experiment (test) of Geldanamycin (NSC122750), the cell expriment (test) of Geldanamycin (NSC122750), the in vivo, in vitro and clinical trial test of Geldanamycin (NSC122750), the EC50, IC50,and affinity,of Geldanamycin (NSC122750), Please contact DC Chemicals.

VT-1598 is a potent, high-affinity, oral inhibitor of fungal sterol 14α-demethylase (CYP51B) with Kd of 13 nM; is more selective for fungal CYP51 than related human CYP enzymes such as CYP3A4; exhibits excellent potency against yeast, dermatophyte, and mold fungal pathogens.

Empesertib(BAY 1161909) is a potent Mps1 inhibitor, with an IC50 of < 1 nM.

MG-132 is a potent, reversible, and cell-permeable 20S proteasome inhibitor which inhibits proteasomal chymotrypsin-like peptidase activity with an IC50 of 24.2 nM.

(R)-RP-6306 (183) can be used for the research of Myt1 mediated diseases and kinds of cancer for slowing the progression of cancer.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels; inhibits SR-BI-dependent uptake of HDL-CE in transfected cells, decreases the fractional catabolic rate of HDL-CE and reduced its hepatic uptake in mice; inhibits HCVcc and HCVpp infection of primary human hepatocytes and/or human hepatoma cell lines and has minimal effects on HCV RNA replication. HCV Infection Phase 2 Clinical

Vandetanib is a potent inhibitor of VEGFR2 with an IC50 of 40 nM.

PF 6260933 is a potent, selective and orally bioavailable MAP4K4 inhibitor with kinase IC50 of 3.7 nM, cell IC50 of 160 nM; possesses excellent kinome selectivity and suitable properties for in vivo pharmacological characterization; significantly improves fasting hyperglycemia (44% reduction in blood glucose, 10 mg/kg, bid); also markedly reduces atherosclerotic lesion area in mice.

DCFH, also known as 2',7'-dichlorodihydrofluorescein, is a fluororescent agent. It is a key chemcial for the dichlorofluorescin (DCFH) oxidation assay.

For the detailed information of Hypaconitine, the solubility of Hypaconitine in water, the solubility of Hypaconitine in DMSO, the solubility of Hypaconitine in PBS buffer, the animal experiment（test） (test) of Hypaconitine, the cell expriment (test) of Hypaconitine, the in vivo, in vitro and clinical trial test of Hypaconitine, the EC50, IC50,and Affinity of Hypaconitine,, please contact DC Chemicals.

Elenestinib (BLU-263) is a potent and orally active tyrosine kinase inhibitor. Elenestinib has the potential for the research of systemic mastocytosis (SM).

A peptide, non-selective melanocortin receptor agonist for treatment for female sexual dysfunction; selectively stimulates solicitational behaviors in the female rat, without affecting lordosis, pacing, or other sexual behaviors, does not cause generalized motor activation; a peptide analogue of α-MSH.